

DAFTAR PUSTAKA

1. Pedoman Tatalaksana Covid-19 5 OP Edisi 4. Jakarta, 4 Januari 2022; Hal: 1-2.
2. Tentang Vaksinasi COVID-19. Available at : <https://covid19.go.id/tentang-vaksin-covid19>
3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptorbinding. *Lancet*. 2020; 395:565-74.
4. Fauziah, Diah Adni., dan Dewi Nurlaela Sari. Efektivitas Vaksinasi terhadap Tingkat Keparahan Covid – 19. 2023. *Jurnal Epidemiologi Kesehatan Indonesia*, Vol. 7, No. 1, Juni – 2023.
5. Cha, Hyeon Hee. So Yun Lim. Ji-Soo Kwon et al. Comparison of Antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-
6. 19. *The Korean Journal of Internal Medicine* 2022;37(2):455-459. Department of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. DOI: <https://doi.org/10.3904/kjim.2021.409>
7. Freund, Ophir. Luba Tau. Tali Epstein Weiss et al. Association of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. Vaccine status and hospitalized severe COVID-19 patients. 10th May, 2022. *PLOS ONE*. <https://doi.org/10.1371/journal.pone.0268050>
8. Song, Songlin. Feihong Wu. Yiming Liu et al. Correlation between chest CT findings and clinical features of 211 COVID-19 suspected patients in Wuhan, China. Department of radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 13th May, 2020. *Infectious Disease Society of America*. DOI: 10.1093/ofid/ofaa171.
9. Pedoman Pencegahan dan Pengendalian *coronavirus disease* (COVID-19) revisi ke-5. Kementerian Kesehatan RI. Juli 2020.
10. Park, Jung Woo. Philip N.P. Lagniton et al. mRNA vaccines for COVID-19: what, why and how. *International Journal of Biological Sciences*. 2021; 17(6): 1446-1460. DOI: 10.7150/ijbs.59233. <http://www.ijbs.com>
11. World Health Organization. WHO Overview cases data. Available from: <https://covid19.who.int/region/searo/country/id>
12. World Health Organization. WHO information note: COVID-19 vaccines overview data. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines>
13. Lotfi, Melika, Michael R. Hamblin, Nima Rezaei. NCBI. US National Library of Medicine National Institutes of Health. COVID-19: transmission, prevention, and potential therapeutic opportunities. Published online, 2020 May 29. *Clin Chim Acta*. 2020 Sep; 508: 254–266. Access : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256510/>
14. Li, Chao. Qifang He. Hebu Qian. *Overview of the pathogenesis of COVID-19*. *Experimental And Therapeutic Medicine* 22: 1011, 2021. Department of critical care medicine, The affiliated Suzhou Hospital of Nanjing Medical University. DOI: 10.3892/ETM.2021.10444. 21 January 2021; page: 3.
15. Röntgen, K. Et al. defining the features and duration of antibody responses to SARS- CoV-2 infection associated with disease severity and outcome. *Sci. Immunol.* 5, eabe0240 (2020).
16. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID19): A literature review. *J Infect Public Health* 2020;13(5):667–73)Antia, A. Et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. *PLoS Biol.* 16, e2006601 (2018).
17. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-

- 19? J Microbiol Immunol Infect 2020;53(3):371–2.
18. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . 2020;(January). Wheatley, A. K. et al. evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat. Commun.* 12, 1162 (2021).
 19. Oh S-J, Lee JK, Shin OS. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. *Immune Netw* [Internet] 2019;19(6):e37. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943173/>Schafer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *J. Exp. Med.* **218**, e20201993 (2021).
 20. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* [Internet] 2015;282(1821):20143085. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707740/>Rodda, L. B. Et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *Cell* 184, 169-183.e117 (2021).
 21. Viner RM, Ward JL, Hudson LD, Ashe M, Patel SV, Hargreaves D, et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. *ArchDis Child* [Internet] 2020;archdischi. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747494/>Lee, W. S. et al. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Preprint at *medRxiv* <https://doi.org/10.1101/2020.12.13.20248143> (2020).
 22. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *J Penyakit Dalam Indones* 2020;7(1):45Akkaya, Munir. Kihyuck Kwak, Susan K. Pierce. B cell memory: building two walls of protection against pathogens. *Nature reviews immunology*; Vol. 20 page: 229-231. April 2020
 23. Liu H, Chen S, Liu M, Nie H, Li H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and MetaAnalysis. *Aging Dis* [Internet] 2020;11(3):668–78. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220287/>Weinreich, D. M. Et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N. Engl. J. Med.* 384, 238-251 (2020).
 24. Liu H, Chen S, Liu M, Nie H, Li H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and MetaAnalysis. *Aging Dis* [Internet] 2020;11(3):668–78. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220287/>
 25. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation* 2020;4–6
 26. Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and metaanalysis. *Metabolism* [Internet] 2020;113:154378. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521361/>
 27. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. *Eur J Med Res* [Internet] 2020;25:64. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708895/>
 28. Malik VS, Ravindra K, Attri SV, Bhadada SK, Singh M. Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and metaanalysis. *Environ Sci Pollut Reserach Int* [Internet] 2020;2020:1–9. Available from:

- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380664/>)
29. Dicks, M. D. J. Et al. 2012. A novel chimpanzee Adenovirus Vector with Low Human Seroprevalence: improved systems for vector derivation and comparative immunogenicity, PLoS ONE. Public Library of Science, 7(7), page. E40385. DOI: 10.1371/journal.pone.0040385
 30. Fatwa MUI No 02 Tahun 2021 tentang Produk Vaksin COVID-19 dari Ainovac Life Sciences, Co. Ltd China dan PT. Biofarma. Available at: <https://mui.or.id/produk/fatwa/29485/fatwa-mui-no02-tahun-2021-tentang-produk-vaksin-covid-19-dari-sinovac-life-sciences-co-ltd-china-dan-pt-biofarma/>
 31. Living guideline therapeutics and COVID-19. World Health Organization. 7 December 2021. WHO ref. number: WHO/2019-nCoV/therapeutics/2021.4.
 32. Simpson, Scott. Fernando, U.Kay, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. *J. Thoracic Imaging* 2020;00:000-000. Available at: www.thoracicimaging.com
 33. Begum J, Mir N, et al. challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine Development DOI : 10.1111/tbed.13804. *transbound Emerg Dis.* 2021;68:1111-1124.
 34. Andrew J. Pollard and Else M. Bijker. A guide to vaccinology: from basic principles to new developments. *Nature Review. Immunology* volume 21 | February 2021
 35. Siegrist C. Vaccines. *Vaccine immunology.* 2013;14-32.
 36. Susan felt. 2006. Analysis of global gene expression in complex biological systems using microarray technology. <https://www.researchgate.net/publication/237758680>
 37. Polard, Andrew J. Else M. Bijker. A guide to vaccinology: from basic principles to new developments. *Nature Reviews Immunology.* 21, 83-100 (2021).
 38. Röntgen, K. Et al. defining the features and duration of antibody responses to SARS- CoV-2 infection associated with disease severity and outcome. *Sci. Immunol.* 5, eabe0240 (2020).
 39. Altmann, Daniel M. Emily M. Whettlock et al. The immunology of long covid. Department of Immunology and Inflammation, Imperia College London, Hammersmith Hospital, London, UK. *Nature review immunology.* 11 July 2023. <https://doi.org/10.1038/s41577-023-00904-7>.
 40. World Health Organization. WHO information note. Available from: [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-condition?gclid=CjwKCAjwh8mlBhB_EiwAsztdBP4hHsz0Mj4x3JhVpw4sEQ3ksJJzyV6Pcm1cgpTgZsX3yKNC92JRnRoCTogQAvD_BwE](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition?gclid=CjwKCAjwh8mlBhB_EiwAsztdBP4hHsz0Mj4x3JhVpw4sEQ3ksJJzyV6Pcm1cgpTgZsX3yKNC92JRnRoCTogQAvD_BwE)
 41. Davis, Hannah E., Lisa McCorkell. Et al. Long COVID: major findings, mechanism and recommendations. *Nature review microbiology* Vol.21. 17 April 2023. page: 133-146. Available from: <https://doi.org/10.1038/s41579-022-00846-2>
 42. Patel, M. A. et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a key pathophysiological mechanism. *Mol. Med.* 28, 122 (2022).
 43. Cysique, L. A. et al. Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation:a longitudinal observational study. Preprint at. *medRxiv.* Available from: <https://doi.org/10.1038/s41579-022-00846-2> (2022).
 44. Woo, M. S. et al. Frequent neurocognitive deficits after recovery from mild COVID-19. *Brain commun.* 2. FCAA205 (2020).
 45. Littlefield, K. M. et al. SARS-CoV-2-specific T cells associated with inflammation and

- reduced lung function in pulmonary post-acute sequelae of SARS-CoV-2. *PLOS Pathog.* 18, e1010359 (2022).
46. Littlefield, K. M. et al. SARS-CoV-2-specific T cells associated with inflammation and reduced lung function in pulmonary post-acute sequelae of SARS-CoV-2. *PLOS Pathog.* 18, e1010359 (2022).
 47. Giron, L. B. et al. Marker of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. *JCI insight*. Available from: <https://doi.org/10.1038/s41579-022-00846-2> (2022).
 48. Yu, J. Z. et al. Lung perfusion disturbance in nonhospitalized post-COVID with dyspnea—magnetic resonance imaging.
 49. Koc, Ho Cheng. Jing Xiao. Et. al. Long COVID and its Management. *International Journal of Biological Sciences*. Ivyspring International Publisher. Int. J. Biol. Sci. 2022, Vol.18(12): 4768-4780. DOI: 10.7150/ijbs.75056.
 50. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nat Med.* 2021; 27.
 51. Halpin SJ, Melvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol.* 2021; 93: 1013-22.
 52. Taboada M, Carinena A, Moreno E, Rodriguez N, Dominguez MJ, Casal A, et al. Post-COVID-19 functional status six-months after hospitalization. *J Infection.* 2021; 82: E31-E3.
 53. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Risk factor for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. *medRxiv.* 2021: 2021.06.24.21259277.
 54. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell.* 2022; 185: 881-95.e20.
 55. ONS. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. In: Statistic OfN, editor. Newport; 2022.
 56. Sigrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in adults discharged from UK hospital after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *Lancet Reg Health- Eu.* 2021; 8.
 57. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized with COVID-19. *Ann Intern Med.* 2021 Apr;174(4):576-578.
 58. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, Noel A, Gunning S, Hatrick J, Hamilton S, Elvers KT, Hyams C, Bibby A, Moran E, Adamali HI, Dodd JW, Maskell NA, Barratt SL. Patient outcomes after hospitalization with COVID-19 and implication for follow-up: result from a prospective UK cohort. *Thorax* 2021 Apr;76(4):399-401.
 59. Chippa, Venu. Abdul Aleem. Fatima Anjum. *Post-Acute Coronavirus (COVID-19) Syndrome*. National Center for Biotechnology Information. 2023, February 3,. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK570608/>
 60. Wu Q, Zhou L, Sun X et al. Altered lipid metabolism in Recovered SARS patients twelve years after infection. *Sci Rep.* 2017 Aug 22;7(1):9110.
 61. Chaudhary R. Kreutz RP. Bliden KP et al. Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and thromboelastometry. *Thromb Haemost.* 2020 Nov;120(11): 1594-1598.
 62. Najafloo, Raziye. Jila Majidi. Alimohamad Asghari et al. Mechanism of Anosmia caused by symptoms of COVID-19 and Emerging Treatments. *ACS Chem Neurosci.* 2021, Oct

- 20; 12(20): 3795-3805. DOI: [10.1021/acscchemneuro.1c00477](https://doi.org/10.1021/acscchemneuro.1c00477).
63. Renaud, Marion. Claire Thibault. Floriane Le Normand. Clinical outcomes for Patients with Anosmia 1 Year After COVID-19 Diagnosis. *JAMA Network Open*. 2021;4(6):e2115352. DOI: [10.1001/jamanetworkopen.2021.15352](https://doi.org/10.1001/jamanetworkopen.2021.15352).
 64. Brancatella A. Rizzi D. Viola N et al. Subacute Thyroiditis after SARS-CoV-2 infection. *J Clin Endocrinol Metab*. 2020 Jul 01;105(7).
 65. Rubino F. Amiel SA. Zimmet P. New onset Diabetes in Covid-19. *N Engl J Med*. 2020 Aug 20;383(8): 789-790.
 66. Zhang, Z., Guo, L., Huang L et al Distinct disease severity between children and older adults with COVID-19; Impacts of ACE2 expression, distribution, and lung progenitor cells. *Clinical infectious diseases: An Official Publication of the Infectious Disease Society of America*. 2021. 73(11): 4154-4165. Available at: <https://doi.org/10.1093/cid/ciaa1911>
 67. Ganie, M.S.F. (2021) Hubungan COVID-19 terhadap Masyarakat Lanjut Usia. *Jurnal Medika Utama (JMH)*. 3(1): 1304-1308.
 68. Widyastuti, W. dkk. Imunosenesens dan Kerentanan Populasi Usia Lanjut terhadap Coronavirus Disease 2019 (Covid-19). *J Respir Indo*. 2020. 40(3): 182-191.
 69. Abbas AK, Lichtman AHPS edisi ke-7. Elsevier; Philadelphia: 2016. *Imunologi Dasar: Fungsi dan Gangguan Sistem Imun*.
 70. Patel ABVA COVID-19 dan penghambat enzim pengubah angiotensin dan penghambat reseptor angiotensin. *J Am Asosiasi Med*. 2020; 323 :1769–1770.
 71. Berlin, I. Daniel Thomas. Anne-Laurence Le Faou. Covid-19 and smoking. *Nicotine and Tobacco research*. 2015; 22(5). DOI: [10.1093/ntr/ntaa059](https://doi.org/10.1093/ntr/ntaa059).
 72. Liu, W. Zhao-Wu Tao. Lei Wang et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J(Engl)*. 2020, May 5;1032-1038. DOI: [10.1097/CM9.0000000000000775](https://doi.org/10.1097/CM9.0000000000000775).
 73. Huttunen R, Heikkinen T, Syrjänen J. Merokok dan akibat infeksi. *J Magang Med* . 2011; 269 :258-269
 74. Rem SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Merokok meningkatkan regulasi reseptor enzim-2 pengubah angiotensin: tempat adhesi potensial untuk virus corona baru SARS-CoV-2 (Covid-19) . *J Klinik Med* . 2020; 9 :841.
 75. Cai G, Boss Y, Xiao F, Kheradmand F, Amos CI. Merokok tembakau meningkatkan ekspresi gen paru-paru ACE2, reseptor SARS-CoV-2 . *Am J Respir Crit Care Med* . 2020; 201 :1557-1559.
 76. Smith JC, Sausville EL, Girish V, dkk. Paparan asap rokok dan sinyal inflamasi meningkatkan ekspresi reseptor SARS-CoV-2 ACE2 di saluran pernapasan . *Sel Pengembang* . 2020; 53 :514-529. [10.1016/j.devcel.2020.05.012](https://doi.org/10.1016/j.devcel.2020.05.012)
 77. Smith JC, Sausville EL, Girish V, dkk. Paparan asap rokok dan sinyal inflamasi meningkatkan ekspresi reseptor SARS-CoV-2 ACE2 di saluran pernapasan . *Sel Pengembang* . 2020; 53 :514-529. [10.1016/j.devcel.2020.05.012](https://doi.org/10.1016/j.devcel.2020.05.012).
 78. Rao, Shitao. Alexandria Lau. Hon-Cheong So. Exploring Disease/traits and Blood Protein causally related to expression of ACE-2, the putative receptor of SARS-CoV-2: A Mendelian Randomization analysis highlight tentative relevance of Diabetes-related traits. *Diabetes Care*. 2020, ul;43(7): 1416-1426. DOI: [10.2337/dc20-0643](https://doi.org/10.2337/dc20-0643).
 79. Karya, Kadek Wisnu., I Made Suwidnya., dan Beny Surya Wijaya. 2021. Hubungan Penyakit Komorbiditas terhadap Derajat Klinis Covid - 19. *Intisari Sains Medis 2021, Vol. 12, No. 2: 708 – 717*. DOI: <https://doi.org/10.15562/ism.v12i2.1143>
 80. Muniyappa, R., and Gubbi, S. 2020. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Endocrinol Metab*. 318(5). E736–E741. <https://doi.org/10.1152/ajpendo.00124.20>

81. Iqbal, A., Iqbal, K., Ali, S. A., Azim, D., Farid, E., Baig, M. D., Bin, T., & Raza, M. (2021). The COVID-19 Sequelae: A Cross-Sectional Evaluation of Postrecovery Symptoms and the Need for Rehabilitation of COVID-19 Survivors. 2(2). <https://doi.org/10.7759/cureus.13080>.
82. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et. al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med.* 2021;27(5):790-2.
83. Aribowo, Kornelis. 2022. Hubungan Status Vaksinasi Tenaga Kesehatan Penyintas Covid - 19 Dengan Hasil Luaran Rawatan Covid - 19 RSUD Se-kota Padang. Universitas Andalas, Padang.
84. Fawzy, Manal S. Hend Ashour. Aya Allah Ashraf Shafie et al. The role of angiotensin-converting enzyme 2 (ACE-2) genetic variations in COVID-19 infection: a literature review. *Egyptian journal of medical human genetics.* 2022; 23:97. <https://doi.org/10.1186/s43042-022-00309-6>

LAMPIRAN

1. Dokumentasi Pengambilan Sampel Penelitian



Data Pasien Penelitian

No	Umur	Riwayat Merokok	Penyakit Komorbid	Derajat Keparahan	Status Vaksinasi	Gejala Klinis
1	≥50	Tidak Merokok	Ada	Severe	Sudah vaksin	Non respirasi
2	<50	Tidak Merokok	Ada	Severe	Sudah vaksin	Non respirasi
3	<50	Tidak Merokok	Tidak ada	Severe	Sudah vaksin	Non respirasi
4	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Kombinasi
5	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Respirasi
6	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Respirasi
7	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
8	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
9	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
10	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Respirasi
11	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Kombinasi
12	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Tidak ada gejala
13	<50	Tidak Merokok	Ada	Non severe	Belum vaksin	Tidak ada gejala
14	<50	Tidak Merokok	Ada	Severe	Belum vaksin	Kombinasi
15	≥50	Tidak Merokok	Tidak ada	Severe	Belum vaksin	Tidak ada gejala
16	<50	Merokok	Ada	Severe	Sudah vaksin	Respirasi
17	≥50	Tidak Merokok	Ada	Non severe	Belum vaksin	Respirasi
18	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Kombinasi
19	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Respirasi
20	<50	Merokok	Tidak ada	Non severe	Belum vaksin	Tidak ada gejala
21	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Kombinasi
22	≥50	Tidak Merokok	Ada	Severe	Sudah vaksin	Kombinasi
23	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
24	<50	Tidak Merokok	Ada	Non severe	Belum vaksin	Non respirasi
25	<50	Tidak Merokok	Ada	Severe	Belum vaksin	Tidak ada gejala
26	<50	Tidak Merokok	Ada	Non severe	Sudah vaksin	Kombinasi
27	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
28	≥50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Non respirasi
29	≥50	Tidak Merokok	Ada	Non severe	Belum vaksin	Non respirasi
30	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
31	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
32	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
33	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Non respirasi
34	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Respirasi
35	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
36	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
37	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Tidak ada gejala

38	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Respirasi
39	<50	Tidak Merokok	Ada	Non severe	Sudah vaksin	Tidak ada gejala
40	<50	Tidak Merokok	Ada	Severe	Belum vaksin	Tidak ada gejala
41	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Respirasi
42	<50	Merokok	Tidak ada	Severe	Sudah vaksin	Non respirasi
43	<50	Tidak Merokok	Ada	Severe	Sudah vaksin	Respirasi
44	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Kombinasi
45	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Kombinasi
46	<50	Tidak Merokok	Tidak ada	Non severe	Belum vaksin	Kombinasi

47	<50	Tidak Merokok	Tidak ada	Severe	Sudah vaksin	Non respirasi
48	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Non respirasi
49	≥50	Merokok	Ada	Severe	Belum vaksin	Respirasi
50	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
51	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Respirasi
52	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Respirasi
53	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Respirasi
54	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
55	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Non respirasi
56	≥50	Tidak Merokok	Ada	Severe	Belum vaksin	Kombinasi
57	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
58	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
59	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
60	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
61	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
62	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
63	≥50	Merokok	Ada	Non severe	Belum vaksin	Non respirasi
64	≥50	Merokok	Ada	Non severe	Belum vaksin	Non respirasi
65	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
66	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
67	<50	Tidak Merokok	Ada	Non severe	Belum vaksin	Respirasi
68	≥50	Tidak Merokok	Ada	Non severe	Belum vaksin	Non respirasi
69	<50	Merokok	Ada	Non severe	Belum vaksin	Non respirasi
70	≥50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
71	≥50	Tidak Merokok	Ada	Non severe	Belum vaksin	Kombinasi
72	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
73	<50	Merokok	Ada	Non severe	Belum vaksin	Respirasi
74	≥50	Tidak Merokok	Ada	Non severe	Belum vaksin	Kombinasi
75	≥50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
76	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
77	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
78	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
79	<50	Tidak Merokok	Ada	Non severe	Belum vaksin	Respirasi
80	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
81	≥50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
82	≥50	Tidak Merokok	Ada	Non severe	Belum vaksin	Non respirasi
83	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
84	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
85	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala

182	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
183	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
184	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
185	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
186	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
187	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
188	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
189	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
190	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
191	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
192	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
193	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala

194	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
195	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
196	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
197	≥50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
198	≥50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
199	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala
200	<50	Tidak Merokok	Tidak ada	Non severe	Sudah vaksin	Tidak ada gejala

UNIVARIAT

Umur

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <50	158	79.0	79.0	79.0
≥50	42	21.0	21.0	100.0
Total	200	100.0	100.0	

Riwayat_Merokok

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Merokok	12	6.0	6.0	6.0
Tidak Merokok	188	94.0	94.0	100.0
Total	200	100.0	100.0	

Penyakit_Komorbid

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ada	40	20.0	20.0	20.0
Tidak ada	160	80.0	80.0	100.0
Total	200	100.0	100.0	

Derajat_Keparahan

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Non severe	180	90.0	90.0	90.0
Severe	20	10.0	10.0	100.0
Total	200	100.0	100.0	

Status_Vaksinasi

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Belum vaksin	54	27.0	27.0	27.0
Sudah vaksin	146	73.0	73.0	100.0
Total	200	100.0	100.0	

Gejala_Klinis

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Kombinasi	19	9.5	9.5	9.5
	Non respirasi	32	16.0	16.0	25.5
	Respirasi	20	10.0	10.0	35.5
	Tidak ada gejala	129	64.5	64.5	100.0
	Total	200	100.0	100.0	

BIVARIAT

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Umur * Gejala_Klinis	200	100.0%	0	0.0%	200	100.0%

Umur * Gejala_Klinis Crosstabulation

Count

		Gejala_Klinis				Total
		Kombinasi	Non respirasi	Respirasi	Tidak ada gejala	
Umur	<50	11	22	16	109	158
	≥50	8	10	4	20	42
Total		19	32	20	129	200

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	9.489 ^a	3	.023
Likelihood Ratio	8.665	3	.034
N of Valid Cases	200		

a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is 3.99.

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Riwayat_Merokok * Gejala_Klinis	200	100.0%	0	0.0%	200	100.0%

Riwayat_Merokok * Gejala_Klinis Crosstabulation

Count

		Gejala_Klinis			
		Kombinasi	Non respirasi	Respirasi	Tidak ada gejala
Riwayat_Merokok	Merokok	1	6	4	1
	Tidak Merokok	18	26	16	128
Total		19	32	20	129

Riwayat_Merokok * Gejala_Klinis Crosstabulation

Count

		Total
Riwayat_Merokok	Merokok	12
	Tidak Merokok	188
Total		200

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	22.436 ^a	3	.000
Likelihood Ratio	20.339	3	.000
N of Valid Cases	200		

a. 3 cells (37.5%) have expected count less than 5. The minimum expected count is 1.14.

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Penyakit_Komorbid * Gejala_Klinis	200	100.0%	0	0.0%	200	100.0%

Penyakit_Komorbid * Gejala_Klinis Crosstabulation

Count

		Gejala_Klinis				Total
		Kombinasi	Non respirasi	Respirasi	Tidak ada gejala	
Penyakit_Komorbid	Ada	11	13	11	5	40
	Tidak ada	8	19	9	124	160
Total		19	32	20	129	200

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	61.834 ^a	3	.000
Likelihood Ratio	61.234	3	.000
N of Valid Cases	200		

a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is 3.80.

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Derajat_Keparahan * Gejala_Klinis	200	100.0%	0	0.0%	200	100.0%

Derajat_Keparahan * Gejala_Klinis Crosstabulation

Count

		Gejala_Klinis				Total
		Kombinasi	Non respirasi	Respirasi	Tidak ada gejala	
Derajat_Keparahan	Non severe	12	26	16	126	180
	Severe	7	6	4	3	20
Total		19	32	20	129	200

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	28.597 ^a	3	.000
Likelihood Ratio	25.627	3	.000
N of Valid Cases	200		

a. 3 cells (37.5%) have expected count less than 5. The minimum expected count is 1.90.

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Status_Vaksinasi * Gejala_Klinis	200	100.0%	0	0.0%	200	100.0%

Status_Vaksinasi * Gejala_Klinis Crosstabulation

Count

		Gejala_Klinis				Total
		Kombinasi	Non respirasi	Respirasi	Tidak ada gejala	
Status_Vaksinasi	Belum vaksin	15	20	12	7	54
	Sudah vaksin	4	12	8	122	146
Total		19	32	20	129	200

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	87.986 ^a	3	.000
Likelihood Ratio	90.078	3	.000
N of Valid Cases	200		

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.13.